InotivNOTVQ -9.91% Days Payable is 39.62 as of Mar. 2026, which is 8% above its 10-year median of 36.68. The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Inotiv ranks worse than 73.3% on this metric.
Inotiv's average Accounts Payable for the
three
months ended in Mar. 2026 was $40.4 Mil. Inotiv's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $93.0 Mil.
Hence, Inotiv's Days Payable for the
three
months ended in Mar. 2026 was 39.62.
The historical rank and industry rank for Inotiv's Days Payable or its related term are showing as below:
NOTVQ'
s Days Payable Range Over the Past 10 Years
Min: 16.29 Med: 36.68 Max: 55.34
Current: 38.63
During the past 13 years, Inotiv's highest Days Payable was 55.34. The lowest was 16.29. And the median was 36.68.
NOTVQ's Days Payable is ranked worse than 73.3% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 68.87
vs NOTVQ: 38.63
Inotiv's Days Payable
increased
from Mar. 2025 (27.36) to Mar. 2026 (39.62).
It may suggest that Inotivdelayed paying its suppliers.
Inotiv Days Payable Related Terms
Inotiv Days Payable Historical Data
* Premium members only.
The historical data trend for Inotiv's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NOTVQ vs NDRA, XWEL, ADVB: Days Payable Comparison
For the Diagnostics & Research subindustry, Inotiv's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inotiv Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Inotiv's Days Payable distribution charts can be found below:
* The bar in red indicates where Inotiv's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Inotiv's Days Payable for the fiscal year that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inotiv (NOTVQ) has a Days Payable of 39.62 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inotiv and its competitors. This is near median its historical median of 36.68. Over the past decade, Inotiv's Days Payable has ranged from 16.29 to 55.34. According to the industry distribution chart, Inotiv ranks #140 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 73.3%.
Is Inotiv's Days Payable too high?
Inotiv's current Days Payable of 39.62 is near median its 10-year median of 36.68. Over the past 10 years, this metric has ranged from a low of 16.29 to a high of 55.34. The Medical Diagnostics & Research industry median Days Payable is 68.87. Inotiv's value of 39.62 is 42.5% below this industry median. Based on the distribution chart, Inotiv ranks #140 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does Inotiv's Days Payable compare to NDRA and XWEL?
According to the Medical Diagnostics & Research industry distribution chart, Inotiv ranks #140 out of 191 companies for Days Payable. This places Inotiv in the lower half of its industry. The industry median Days Payable is 68.87. Inotiv's value of 39.62 is 42.5% below this benchmark. Historically, Inotiv's own Days Payable has ranged from 16.29 to 55.34 over the past decade. While the company's 10-year median is 36.68 vs. the industry median of 68.87, Inotiv has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 68.87, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Inotiv's current Days Payable of 39.62 is 42.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Inotiv and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 68.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inotiv's current Days Payable is 39.62, which is near median its own 10-year median of 36.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (NOTVQ) is currently considered Possible Value Trap. The stock's GF Value™ is $1.68, compared to a current price of $0.01 — trading 99.4% below its estimated fair value. The current Days Payable is 39.62, which is near median its 10-year median of 36.68 and 42.5% below the Medical Diagnostics & Research industry median of 68.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Inotiv (NOTVQ), the current Days Payable is 39.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NOTVQ has been successfully added to your 